aTyr Pharma
ATYR
29 hedge funds and large institutions have $5.25M invested in aTyr Pharma in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 6 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.19% less ownership
Funds ownership: 2.71% → 2.52% (-0.19%)
6% less funds holding
Funds holding: 31 → 29 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
43% less capital invested
Capital invested by funds: $9.22M → $5.25M (-$3.97M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$156K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$18.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.7K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$10.4K |
| 5 |
Two Sigma Investments
New York
|
+$2.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$406K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$209K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$83K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$35K |
| 5 |
Millennium Management
New York
|
-$26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
26
Bridgeway Capital Management
Houston,
Texas
| – | -$83K | -7,336 | Closed |
|
|
ARTA
27
A.R.T. Advisors
New York
| – | -$35K | -3,094 | Closed |
|
|
28
Millennium Management
New York
| – | -$26K | -2,302 | Closed |
|
29
Jane Street
New York
| – | -$15K | -1,338 | Closed |
|
|
TSS
30
Two Sigma Securities
New York
| – | -$8K | -733 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | +$59 | +7 | New |
|
32
Simplex Trading
Chicago,
Illinois
| – | +$176 | +21 | New |
|
ATYR Hedge Fund Activity: Q4 2018 in Review
29 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2018, worth a combined $5.25M — down 43% from $9.22M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ATYR and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $156K. The largest seller was Artal Group, exiting entirely with an estimated $406K sold.
- 29 institutional investors held aTyr Pharma (ATYR) as of Q4 2018, down from 31 in Q3 2018.
- Funds reported $5.25M of aTyr Pharma stock for Q4 2018, down 43% quarter-over-quarter.
- 4 funds opened new aTyr Pharma positions in Q4 2018 and 6 closed out, a net change of -2 holders.
- The largest aTyr Pharma buyer in Q4 2018 was Renaissance Technologies, an estimated $156K added.
- The largest aTyr Pharma seller in Q4 2018 was Artal Group, an estimated $406K sold.
Based on aggregated 13F filings for Q4 2018.